@article{ref1,
title="The association between leukotriene-modifying agents and suicidality: a review of literature",
journal="Psychosomatics",
year="2018",
author="Khalid, Faiza and Aftab, Awais and Khatri, Sumita",
volume="59",
number="1",
pages="19-27",
abstract="BACKGROUND: In 2008 Food and Drug Administration issued a warning regarding a possible association between leukotriene-modifying agents and suicidality. <br><br>OBJECTIVE: The warning remains controversial and this review of literature is an attempt to examine the evidence on the matter. <br><br>METHODS: Literature search on PubMed. <br><br>RESULTS: The data supporting a relationship between leukotriene-modifying agents and suicidality comes primarily from reviews of individual safety reports in adverse event databases; it is subject to considerable reporting bias and does not control for confounding factors. Case-control and cohort studies as well as data from clinical trials do not support an association between leukotriene-modifying agents and suicidality. The data from ecological studies offers strong evidence of a lack of positive association between leukotriene-modifying agents and suicide outcomes (attempts and deaths) at the population level. Furthermore, there is no pharmacological mechanism that would explain an association between the two. <br><br>CONCLUSION: Overall, the weight of higher quality evidence casts doubt on the association (especially at population level), but is not enough to conclusively disprove the association at an individual level.<br><br>Copyright © 2017 The Academy of Psychosomatic Medicine. Published by Elsevier Inc. All rights reserved.<p /> <p>Language: en</p>",
language="en",
issn="0033-3182",
doi="10.1016/j.psym.2017.08.005",
url="http://dx.doi.org/10.1016/j.psym.2017.08.005"
}